Skip to content
HowShorted

Portola Pharmaceuticals, Inc. short interest in 2019

In 2019, Portola Pharmaceuticals, Inc.'s disclosed short interest ran from 28.32% of shares outstanding on 15 Jan 2019 to 19.52% on 31 Dec 2019, a change of -8.80 percentage points. The year's high was 28.32% on 15 Jan 2019 and its low 17.89% on 13 Dec 2019, averaging 21.76% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.22 days on 31 Oct 2019. Full history: Portola Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for Portola Pharmaceuticals, Inc. in 2019

2019 in figures

Start of year
28.32% (15 Jan 2019)
End of year
19.52% (31 Dec 2019)
Change
-8.80 pp
High
28.32% (15 Jan 2019)
Low
17.89% (13 Dec 2019)
Average
21.76%
Highest days to cover
30.22 (31 Oct 2019)
SEC filings marked
9

Every report in 2019

Portola Pharmaceuticals, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201928.32%7.69results (8-K)
31 Jan 201927.83%11.95
15 Feb 201925.32%12.90
28 Feb 201922.93%11.58
15 Mar 201923.27%9.4510-K filed, results (8-K)
29 Mar 201921.36%18.00
15 Apr 201918.71%12.11
30 Apr 201918.64%14.80
15 May 201918.24%10.1210-Q filed, results (8-K)
31 May 201918.74%12.00
14 Jun 201920.19%12.80
28 Jun 201920.76%12.47
15 Jul 201921.86%19.70
31 Jul 201923.02%22.78
15 Aug 201924.26%7.8110-Q filed, results (8-K)
30 Aug 201921.89%15.89
13 Sep 201923.18%14.18
30 Sep 201923.06%16.96
15 Oct 201922.83%24.65
31 Oct 201922.92%30.22
15 Nov 201919.15%15.5810-Q filed, results (8-K)
29 Nov 201918.25%19.08
13 Dec 201917.89%18.35
31 Dec 201919.52%16.43

See also: Portola Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.